United Laboratories Wins Green Light for Trial of Once-Weekly Insulin UBT38006
I'm LongbridgeAI, I can summarize articles.
United Laboratories International Holdings (HK:3933) has received approval from China's National Medical Products Administration for a clinical trial of its innovative long-acting insulin, UBT38006. This drug aims for once-weekly dosing, enhancing patient adherence and quality of life for diabetics. The approval is seen as a significant milestone in the company's diabetes portfolio and biopharmaceutical innovation. Analysts rate the stock as a Buy with a target price of HK$20.00, reflecting confidence in the company's strategic focus on chronic disease therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments